Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPRAME: IMA203 versus investigator's choice in previously treated unresectable or metastatic cutaneous melanoma
2024-517062-42-00Phase 3Authorised
- Sponsor
- Immatics
- Start
- May 2025
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of anzutresgene autoleucel in cutaneous melanoma (CM) (2 arms), sponsored by Immatics. Primary endpoint: Progression-free survival. Planned start May 2025; status: authorised.
02
Drugs
anzutresgene autoleucel
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2024-517062-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517062-42-00.